profit from every ₹100 of sales.
₹0₹100
Suven Life Sciences
₹279.95+2.06% today
+63.7% in 1 year
1-year low ₹126.651-year high ₹392.05
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Suven Life Sciences sold, what it kept, and what it did with the cash.
Sales went from ₹135 million in 2023 to ₹71.1 million in 2026, with -₹2.76 billion of profit last year.
SalesProfit
Suven Life Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Suven Life Sciences | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.6× · Expensive |
AI analysis
An AI analyst reads Suven Life Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 135 | 117 | 67 | 71 | |
| 132 | 110 | 67 | 71 | |
| -1,319 | -1,343 | -1,716 | -2,901 | |
| -1,114 | -994 | -1,549 | -2,706 | |
| -1,183 | -1,051 | -1,607 | -2,763 | |
| -6.63 | -4.82 | -7.37 | -12.13 | |
| 97.3% | 93.9% | 100.0% | 100.0% | |
| -974.3% | -1,148.5% | -2,578.1% | -4,077.7% | |
| -873.5% | -898.6% | -2,415.1% | -3,884.1% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 3,889 | 2,849 | 1,352 | 6,242 |
| Cash | 370 | 149 | 150 | 83 |
| Total debt | 16 | 7 | 0 | 167 |
| Total liabilities | 136 | 149 | 252 | 328 |
| 3,753 | 2,700 | 1,100 | 5,914 | |
| 218 | 218 | 218 | 228 | |
| -23.5% | -29.3% | -109.6% | -34.1% | |
| -31.5% | -38.9% | -146.1% | -46.7% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| -1,160 | -826 | -1,541 | -3,018 | |
| 29 | – | 373 | 51 | |
| -1,189 | -826 | -1,914 | -3,069 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | 0 | 13 | 18 |
Valuation
- –
- –
- –
- 11.7×
- 1,111.8×
- –
- –
- -3.9%
- -3.5%
- –
Profitability
- 100.0%
- -4,077.7%
- -3,884.1%
- –
- -34.1%
- -49.1%
- –
- –
- –
- –
Growth
- −19.3%
- –
- –
- –
- +1.5%
Financial health
- –
- 0.03
- –
- -1,750.2×
- 17.69
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 948
Bottom 5%of 868
Bottom 23%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
49No pass
Benjamin Graham
42No pass
Philip Fisher
56No pass
Peter Lynch
42No pass
Joel Greenblatt
2No pass
Charlie Munger
61Pass
Terry Smith
59No pass
Questions about Suven Life Sciences
Is Suven Life Sciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Suven Life Sciences AI analysis
What does Suven Life Sciences do?
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. It is in Drug Manufacturers - Specialty & Generic, based in Hyderabad, India.
Is Suven Life Sciences stock halal?
Yes. Suven Life Sciences passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has Suven Life Sciences stock done over the past year?
Up 63.7% over the past twelve months, to ₹279.95. It traded between ₹126.65 and ₹392.05 and is 28.6% below its high.
Who are Suven Life Sciences's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Suven Life Sciences's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.